Menarini Silicon Biosystem, Bologna, Italy, has introduced MSBiosuite, a Cloud-based data analytics solution for liquid biopsy and formalin-fixed, paraffin-embedded (FPPE) tissue analysis. The system is designed to bridge the gap between sequencing data and consolidated results.

MSBiosuite was developed in partnership with BlueBee, Rijswijk, the Netherlands, a global genomic data platform company. The newly integrated system provides optimized next-generation sequencing (NGS) data processing, analysis, interpretation, and reporting for users of Menarini NGS library preparation kits. The system meets clinical data security and compliance requirements and guarantees data residency within the region of choice.


Fabio Piazzalunga, Menarini Silicon Biosystems.

“We have removed the complexity and high barrier that traditionally exist for bioinformatics, data management, and clinical data compliance and security,” says Fabio Piazzalunga, CEO of Menarini Silicon Biosystems. “With MSBiosuite, we now offer an integrated data solution that completes our single-cell liquid biopsy and FFPE workflows and will support our customers in getting to actionable results with efficiency and confidence.”

MSBiosuite is designed to automate the processing of raw sequencing data generated using the company’s Ampli1 and DepArray NGS kits for single circulating tumor cells and FFPE tissue analysis, respectively. The system also provides information on copy number profiling and somatic variants.


Hans Cobben, BlueBee.

“Through this partnership, BlueBee enables Menarini Silicon Biosystems to make the data tangible, actionable, and compliant with global health data regulations,” says Hans Cobben, CEO of BlueBee.

A clinical interpretation report is available with the Ampli1 and DepArray OncoSeek pipelines. Clinically relevant variants are classified by levels of known significance, and layers of diagnostic, prognostic, therapeutic, and biomarker evidence are integrated. The service also incorporates deep scientific and clinical analysis of each patient’s molecular data in order to identify and prioritize the best clinical trial options.

MSBiosuite is now available in Europe and will be available in the United States later this year. The system is for research use only and not for use in diagnostic procedures.

For more information, visit Menari Silicon Biosystems and BlueBee.